
On-line Table: Enhancement characteristics of all newly formed lesions^a


	Participant	T2-FLAIR	Manganese	Gadolinium	
Lesion No.	No.	Appearance	Appearance	Enhancement?	Manganese Enhancement Type
1	1	2 Days pre-Mn ²⁺	0 day post-Mn ²⁺	Yes	Central lesion enhancement, peripheral blush
2	3	7 Days pre-Mn ²⁺	N/A	Yes	N/A
3	3	7 Days pre-Mn ²⁺	N/A	Yes	N/A
4	3	27 Days post-Mn ²⁺	N/A	Yes	N/A
5	5	31 Days post-Mn ²⁺	31 Days post-Mn ²⁺	No	Punctate
6	5	31 Days post-Mn ²⁺	31 Days post-Mn ²⁺	No	Blush
7	5	31 Days post-Mn ²⁺	31 Days post-Mn ²⁺	No	Punctate
8	5	31 Days post-Mn ²⁺	31 Days post-Mn ²⁺	Yes	Punctate
9	5	31 Days post-Mn ²⁺	31 Days post-Mn ²⁺	Yes	Blush
10	5	31 Days post-Mn ²⁺	31 Days post-Mn ²⁺	Yes	Blush
11	5	31 Days post-Mn ²⁺	31 Days post-Mn ²⁺	Yes	Punctate
12	5	31 Dasys post-Mn ²⁺	31 Days post-Mn ²⁺	Yes	Punctate
13	5	38 Days post-Mn ²⁺	31 Days post-Mn ²⁺	Yes	Punctate
14	5	38 Days post-Mn ²⁺	N/A	No	N/A

Note:— N/A indicates not applicable.



ON-LINE FIG 1. Pre- and postmangafodipir images show enhancement of the choroid plexus but not chronic (non-gadolinium-enhancing) MS lesions in 2 participants. T2-FLAIR (*A* and *D*) and T1-weighted (*B* and *E*) images from participants 2 (*A*–*C*) and 3 (*D*–*F*). Subtraction images (*C* and *F*) were generated by subtracting the baseline T1-weighted scan from the postmangafodipir T1-weighted scan (30 minutes after injection for participant 2 and 4 hours after injection for participant 3). Typical manganese enhancement of the choroid plexus (*arrows*) occurs soon after injection, but no enhancement in nonacute MS lesions was noted (*triangles*).

^a Fourteen new T2-FLAIR lesions developed during the study. Eight were first seen 31 days after mangafodipir injection, and 2 were first seen at day 38 postmangafodipir. Three lesions visible on T2-FLAIR were gadolinium-enhancing before manganese injection, of which 1 enhanced with manganese. One lesion was noted 27 days postmangafodipir and did not enhance with manganese.



ON-LINE FIG 2. (in 2 parts). All lesions that developed during the course of this study in participant 5, a 33-year-old woman with relapsing-remitting MS. Lesion 13, demarcated by a *star*, enhanced on TI-weighted images with manganese before clear visibility on FLAIR.